We analyzed data from a prospective observational cohort study that included 108 adult intensive care units (ICUs) in 41 United States hospitals. Use of vancomycin (defined daily doses per 1,000 patient-days), nosocomial infection rates, and proportion of all Staphylococcus aureus isolates resistant to methicillin (MRSA rate) were recorded from January 1996 through November 1997. The median rate of vancomycin use was lowest in coronary care ICUs and highest in general surgical ICUs. Prior approval before use of vancomycin was required in only 26 (24%) of the 108 ICUs. In a multivariate linear regression model, rates of MRSA, central line -associated bloodstream infection, and the type of ICU were independent predictors of vancomycin use. None of the vancomycin control practices was associated with lower rates of vancomycin use; however, it is important to recognize that this database was not designed to measure rates of inappropriate use. Vancomycin use is heavily determined by rates of endemic MRSA and central line -associated bloodstream infection. Efforts to reduce these rates through infection control activities should be included in hospitals' efforts to reduce vancomycin use.
Strains of Staphylococcus aureus resistant to methicillin
was associated with decreased susceptibility to vancomycin of S. aureus from patients in the United States and Japan [12, 13] . (MRSA) and to other antimicrobial agents have become commonplace in hospitals in the United States [1, 2] . S. aureus, Since the Centers for Disease Control and Prevention (CDC) published ''Recommendations for Preventing the Spread of together with coagulase-negative staphylococci, account for roughly half of nosocomial central line -associated bloodVancomycin Resistance'' in 1995, investigators have reported that 30% -80% of vancomycin used in hospitals was inapprostream infections and are commonly resistant to methicillin and other drugs, leaving vancomycin as the only effective agent priate according to the published criteria [14 -21] . for treating infections caused by these types of organisms [3, 4] . Therefore, it is not surprising that the use of vancomycin See editorial response by Wenzel and Wong has increased over the past decade [5 -7] . Unfortunately, along on pages 1126 -7. with this increase in vancomycin use, resistance has increased among certain organisms. There has been a 20-fold increase in the proportion of enterococci reported as resistant to vancoEfforts to improve antimicrobial use in hospitals have genermycin in hospitals participating in the National Nosocomial ally focused on cost-saving interventions [6, 22] , although some Infections Surveillance (NNIS) system, with highest rates studies have documented decreased rates of colonization or among isolates from patients in intensive care units (ICUs) [3, infection with antimicrobial-resistant bacteria after interven-8]. Vancomycin exposure has been shown to be a risk factor tions [23 -25] . National organizations, including the CDC, the for infection with vancomycin-resistant enterococci [9 -11] and National Foundation for Infectious Diseases, the Infectious Diseases Society of America, and the Society for Healthcare Epidemiology of America, have published consensus statements calling for a system to monitor and improve antimicrobial use Received 24 August 1998; revised 22 December 1998. in hospitals in the United States [26, 27] . Despite this consen- [28] . Therefore, the four hospitals that initially had not returned the survey pneumonia, and catheter-associated urinary tract infection) and the number of patient admissions, days of device utilization by were contacted regarding clinical practice guidelines, and their responses were included in this analysis. patients (device-days), and total inpatient days for the ICU, allowing the calculation of device-associated infection rates Data were analyzed with SAS Release 6.12 software (SAS Institute, Cary, NC). Selected factors potentially associated (i.e., infections per 1,000 device-days), device utilization rates (percentage of patient-days in which specific devices were in with increased or decreased use of vancomycin (e.g., ICU or hospital characteristic, device utilization rates, nosocomial inuse), and average length of stay.
Under the ICARE component, hospitals reported the amount fection rates, MRSA rates, or antimicrobial control practices) were evaluated. The relationship between continuous variables (in grams) of vancomycin administered intravenously to patients and the proportion of S. aureus isolates from clinical and vancomycin use was assessed by means of Spearman's rank correlation coefficient, while for categorical variables the specimens that were resistant to methicillin (MRSA rate). Microbiological data were reported for each ICU, all non-ICU medians were compared with the Kruskal-Wallis test. All reported P values are two-tailed. To assess the joint influence of inpatient wards combined, and all outpatient areas combined. Pharmacy data were reported for the same hospital strata, but these factors, we used stepwise linear regression techniques to develop a model for vancomycin use, identifying the most outpatient areas were omitted. All S. aureus isolates, whether associated with hospital-or community-acquired infection or important main effects and first-order interaction terms. colonization, were reported. Duplicate isolates were excluded; these were defined as isolates of the same organism with the Results same antimicrobial resistance pattern that were recovered from the same patient, regardless of the site of isolation. Amounts Description of sites. During the study period, 41 hospitals reported a median of 12 months' worth of data from a total of of parenteral vancomycin were standardized by conversion to defined daily doses (DDDs), where 1 DDD is equivalent 108 adult ICUs. The hospitals were in 19 states and had a median capacity of 385 beds (range, 147 -1,206); 28 (68%) to 2 g.
For each ICU, pooled mean rates for the study period were were affiliated with a teaching institution, and 4 (10%) were Veterans Affairs medical centers. The ICUs included 27 MSUs, calculated for device-associated infection, device utilization, average length of stay, MRSA, and vancomycin use. For exam-20 CCUs, 19 MICUs, 19 general SICUs, 12 cardiothoracic ICUs, and 11 ''other'' ICUs. The number of beds in the ICU, ple, the pooled mean rate of vancomycin use was calculated by dividing the total number of DDDs by the total number of median length of stay, and rates of central line -associated bloodstream infection, catheter-associated urinary tract infecpatient-days reported over the study period and was expressed as DDDs per 1,000 patient-days. MRSA rates were calculated tion, and central line utilization each varied significantly among the different types of ICUs ( When we compared the median rate of vancomycin use for importance of the remaining variables depended entirely on their relationship with vancomycin use in the remaining 96 the ICUs that each had various vancomycin control practices and a method of disseminating guidelines to the median rate
ICUs.
An interaction between central line -associated bloodstream for those ICUs that did not have such practices and methods, no control practice or method of dissemination was associated infection and type of ICU (i.e., all noncardiothoracic ICUs) was found to be significant and remained in the final model. The with lower rates of vancomycin use (table 2) . However, several control practices (i.e., automatic stop orders, participation final model showed that an increased central line -associated bloodstream infection rate in any type of ICU except cardioof pharmacists on rounds with ICU clinicians, use of criteria for appropriate use, and use of pocket guides by physicians) thoracic ICUs, an increased rate of MRSA among all inpatient isolates of S. aureus, and cardiothoracic ICUs (regardless of were associated with significantly higher rates of vancomycin use (table 2). These counterintuitive findings (i.e., of higher central line -associated bloodstream infection rate) were associated with significantly higher vancomycin use, while CCUs use in ICUs using control practices) are partially explained by higher rates of MRSA and/or of central line -associated were the only factor associated with lower vancomycin use (table 4) . In addition, the final model controlled for the effects bloodstream infection at hospitals using these control measures (table 3) . Because MRSA rates and bloodstream infecof ICU ''A'' and ICU ''B,'' which used vancomycin at extremely high rates. tion rates are related to both vancomycin use and control policies, these rates confound the effect of the vancomycin control policy on vancomycin use and must be controlled for Discussion to determine the independent effect of antimicrobial control practices on vancomycin use.
The concern that improved antimicrobial use should be a public health priority has been intensified since the isolation To assess the independent importance of factors identified in univariate analysis, a stepwise linear regression analysis was of S. aureus with decreased susceptibility to vancomycin in patients in the United States and Japan [12, 13, 31] . Determinperformed. Because the rate of MRSA was calculated only if §10 isolates were reported, no MRSA rate was available for ing effective mechanisms to decrease vancomycin use at hospitals has been a great challenge to pharmacy and infection consome ICUs. Therefore, we used the total inpatient MRSA rate in the final modeling process. The final model included only trol personnel [25, 32, 33] . In our study, rates of MRSA, rates of central line -associated bloodstream infection, and type of the 98 ICUs that reported sufficient data concerning all factors under investigation. Including ICU ''A'' and ICU ''B'' (both ICU were independent predictors of vancomycin use in adult ICUs. After controlling for these factors, our study did not at the same hospital) in the model significantly changed the / 9c65$$my26 04-06-99 08:27:58 cidal UC: CID tially appeared to be associated with lower vancomycin use (table 2) [28] , the influence of two ICUs (''A'' and ''B'') at the same hospital, a hospital that did not use such guidelines, identify a specific antimicrobial control practice that was associated with lower rates of vancomycin use.
may have confounded the preliminary analysis. The role of influential data points has been illustrated in other analyses of Effective methods of reducing vancomycin use at one institution may be ineffective at others. The reasons for this may be NNIS data [39] and highlights the importance of examining data from multicenter studies for these effects. multifactorial and difficult to assess. Our data illustrate some of the difficulties involved in evaluating the effectiveness of
The lack of association between decreased vancomycin use and antimicrobial control practices must be interpreted with antimicrobial control programs at multiple institutions. First, we observed that vancomycin use varied by the ICU type, caution. Our survey instrument did not record all aspects of antimicrobial control practices; possible aspects of control reflecting the types of patients cared for in the ICU. Any surveillance system of antibiotic use should account for differpractices not included in our analysis include curbside consultation with infectious diseases physicians, attitudes of ICU direcences in patient type. In addition, vancomycin use was directly related to ICU or microbiological characteristics that differ tors and ICU attending physicians, and local expert opinions. This was not an intervention study, and we did not assess the from hospital to hospital, such as the rate of MRSA or central line -associated bloodstream infections. This observation is effect of antimicrobial-use control programs on vancomycin use within each individual ICU. Therefore, this analysis did supported by data reported from NNIS hospitals, which showed that 60% of pathogens isolated from patients with central linenot assess the change in vancomycin use over time in a specific ICU, but rather differences in use based on differing ICU or associated bloodstream infections are pathogens commonly treated with vancomycin (i.e., coagulase-negative staphylohospital characteristics. Comparison of use in an ICU before and after intervention is needed to assess the importance of cocci, enterococci, and S. aureus) [4, 34] .
Of interest is the finding that the bloodstream infection rate specific aspects of antimicrobial control practices. Likewise, these data did not incorporate a measure of inappropriate use, was an independent predictor of vancomycin use in all types of ICUs except cardiothoracic units. Why there is a lack of which, while ideal, would be very labor-intensive in a study of this magnitude. Although the hospitals participating in NNIS dependence between vancomycin use and the bloodstream infection rate in cardiothoracic ICUs is unclear. Two factors to and specifically in Project ICARE tend to be larger than the typical hospital in the United States, because we limited the be considered are that these patients may commonly receive prophylactic vancomycin, which would suppress bloodstream analysis to adult ICUs this difference will unlikely limit the generalizability of our findings to adult ICUs throughout the infections. In addition, the length of stay of patients in these units tends to be short, and the bloodstream infections may United States. In addition, we controlled for ICU and hospital-specific chargo undiagnosed during their stays in the cardiothoracic ICU. Regardless, efforts to reduce vancomycin usage in ICUs may acteristics associated with vancomycin use in our multivariate model; therefore, we believe the demonstration by our data require that hospitals focus increased attention on the prevention of central line -associated bloodstream infection and crossthat vancomycin use was linked to rates of endemic MRSA and central line -associated bloodstream infection is applicable transmission of MRSA between patients [35, 36] . Once these factors with major impact are dealt with, the relative importance to most adult ICUs at hospitals in the United States. If hospitals can recognize this link, we believe our data will help hospitals of antimicrobial control practices may be assessed.
